Morgan Stanley Adjusts Novo Nordisk Rating Amid Growth and Patent Concerns

By EC Assets · Published 11 September 2026

Morgan Stanley has adjusted its rating on Novo Nordisk, over growth prospects and potential patent cliffs. The investment firm recently downgraded Novo Nordisk, leading to a dip in the company's shares. These rating changes reflect Morgan Stanley's evolving view on the pharmaceutical giant's mid-term outlook. Morgan Stanley downgraded Novo Nordisk to Underweight from Equal-weight. This downgrade was based on the firm's view of slowing growth for Novo Nordisk's GLP-1 franchise. This lucrative franchise includes the weight loss medication Wegovy and a type 2 diabetes treatment. The firm's analysts also expressed concerns regarding potential competition in the weight loss drug market. Separately, Morgan Stanley expects a trial for Novo Nordisk's blockbuster weight-loss drug in Alzheimer's treatment to fail. This expectation contributed to the firm's decision to slash its rating on the company. Novo Nordisk's stock was among the major companies whose shares moved on the week's news. Earlier, Morgan Stanley upgraded Novo Nordisk to Equal-weight from Underweight on March 3. This upgrade occurred after a recent share price decline. The firm stated that this decline brought the valuation more in line with the company's mid-term risks. At that time, Morgan Stanley also adjusted the price target on the stock to $40 from $42. The investment firm's varied ratings reflect ongoing assessments of Novo Nordisk's product pipeline and market position. Concerns about the growth trajectory of key drug franchises and upcoming patent expirations remain central to analyst evaluations. The outcome of clinical trials for new indications, such as Alzheimer's disease, also plays a significant role in investment sentiment. The pharmaceutical sector continues to face scrutiny over drug development, market competition, and patent protection. Investor focus will likely remain on Novo Nordisk's progress in clinical trials, competitive landscape shifts, and updates regarding its GLP-1 franchise. This article is intended for informational purposes only. It does not constitute investment advice.